EXELIXIS, INC. cotiza a 59.51 USD y tiene una capitalización bursátil de $14.7B. En los últimos 12 meses ha facturado $2.4B con un margen de flujo de caja libre del 37.8%. Cotiza a 12.6 veces su flujo de caja libre (P/FCF) y a un PER de 17.1. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and CO…
| Periodo | 2026-10 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.91 | $0.87 | $0.94 |
| Estimado | $0.90 | $0.87 | $0.76 | $0.81 |
| Sorpresa | — | +4.6% | +14.5% | +16.0% |
| Métrica | EXEL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 96.4% | 57.0% | +39.4% |
| Operating Margin | 37.6% | -38.6% | +76.2% |
| Net Margin | 33.7% | -33.6% | +67.3% |
| FCF Margin | 37.8% | -13.9% | +51.6% |
| ROE | 36.2% | -40.4% | +76.6% |
| ROA | 27.5% | -32.0% | +59.5% |
| Current Ratio | 3.56 | 2.84 | +0.72 |
| Debt / Equity | — | 0.28 | — |